Tern Therapeutics have published a press release and written a community letter to update you on their progress in the TTX-381 and TTX-181 clinical trials. These are AAV9 based gene therapies, TTX-381 is looking to address vision loss and has been taking place in the UK at Great Ormond Street Hospital (GOSH). TTX-181 is a single patient trial in Brazil. The data were presented at the 21st Annual WORLD SymposiumTM earlier this year.

You can read the press release at the link below

http://www.bdfa-uk.org.uk/…/CLN2-Batten-Community…

If you have any questions about the press release or the data, please contact Jo joannanightingale@bdfa-uk.org.uk